Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma [Phase 3]
Phase 3 study evaluating Orelabrutinib plus R-CHOP in treatment-naïve patients with the MCD subtype of diffuse large B-cell lymphoma (DLBCL)…
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating loncastuximab tesirine in combination with ibrutinib for diffuse large B-cell lymphoma and mantle cell lymphoma w…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]
Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in Fe…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma [Phase 2]
A Phase 2 study evaluating the combination of copanlisib and nivolumab in patients with recurrent or refractory diffuse large B-cell lymphom…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL [Phase 1, Phase 2]
Phase 1/2 trial update for CX-2029 in solid tumors and DLBCL completed; aims to identify safe and active dose levels.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) [Phase 1]
A Phase 1 study of Betalutin in relapsed or refractory diffuse large B-cell lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial update evaluating ibrutinib in combination with standard immuno-chemotherapy in younger, high-risk adults with diffuse large B…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL [Phase 2]
Phase 2 trial update investigating copanlisib with rituximab and CHOP for previously untreated diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: CD30 Imaging in Diffuse Large B-cell Lymphoma [Phase 3]
Phase 3 clinical trial update on CD30 imaging in diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL [Phase 3]
A Phase 3 trial comparing SIBP-02 + Rituximab + CHOP versus a reference regimen in previously untreated CD20+ diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating obinutuzumab, polatuzumab vedotin, and lenalidomide in relapsed or refractory follicular lymphoma and rituximab w…
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating selinexor with R-CHOP followed by selinexor maintenance for untreated EBV-positive diffuse large B-cell lymphoma.…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) [Phase 2]
Phase 2 safety trial evaluating lisocabtagene maraleucel (JCAR017) for relapsed/refractory B-cell non-Hodgkin lymphoma in the outpatient set…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab in relapsed/refractory gray-zone lymphoma, primary CNS lymphoma, and other extranodal diffuse large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma [Phase 2]
Phase 2 trial update for CD19-targeted CAR T cells in relapsed/refractory non-Hodgkin lymphoma, including DLBCL and follicular lymphoma, wit…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: DPX-Survivac and Checkpoint Inhibitor in DLBCL [Phase 2]
Phase 2 clinical trial update evaluating DPX-Survivac in combination with a checkpoint inhibitor for adult diffuse large B-cell lymphoma (DL…
-
CLINICAL_TRIALS trial_result · 2023-10-25Clinical Trial Update: MabionCD20 Compared to MabThera in Lymphoma Patients [Phase 3]
A Phase 3 trial comparing MabionCD20 to MabThera in patients with diffuse large B-cell lymphoma has completed and results were posted in 202…
-
CLINICAL_TRIALS trial_result · 2023-10-17Clinical Trial Update: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL [Phase 2]
Phase 2 trial update investigating ZR2 followed by immunochemotherapy in elderly patients with newly diagnosed diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2023-10-11Clinical Trial Update: Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects [Phase 2]
Phase 2 clinical trial update for BEBT-908 in relapsed or refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating obinutuzumab, rituximab, polatuzumab vedotin, and venetoclax in relapsed/refractory follicular lympho…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of acalabrutinib with R-CHOP in patients with non-Hodgkin lymphoma (diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2023-09-14Clinical Trial Update: Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL [Phase 1, Phase 2]
This completed Phase 1/2 trial studied lenalidomide in combination with RICE chemotherapy followed by lenalidomide maintenance after autolog…
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL [Phase 2]
Phase 2 trial evaluating chidamide plus R-GemOx as salvage therapy for transplant-ineligible patients with relapsed/refractory diffuse large…
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma [Phase 3]
Phase 3 trial evaluating acalabrutinib combined with R-miniCHOP in older adults with untreated diffuse large B-cell lymphoma is currently re…
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL [Phase 1, Phase 2]
Clinical trial update for tazemetostat as a single agent and in combination in B-cell lymphomas and solid tumors completed with results post…